Systemic Treatment of Ewing Sarcoma: Current Options and Future Perspectives

Systemic Treatment of Ewing Sarcoma: Current Options and Future Perspectives

Forum of Clinical Oncology

Volume 12 (2021): Issue 3 (December 2021)

By:

Jose Duran Moreno, Georgios Papageorgiou, Ioanna Gazouli and Anastasios Kyriazoglou

Open Access

|Feb 2022

References

Bellan DG, Filho RJ, Garcia JG, de Toledo Petrilli M, Maia Viola DC, Schoedl MF, Petrilli AS. Ewing's sarcoma: Epidemiology and prognosis for patients treated at the Pediatric Oncology Institute, IOP-GRAACC-UNIFESP. Rev Bras Ortop. 2015 Dec 8;47(4):446–450. doi:<a href="https://doi.org/10.1016/S2255-4971(15)30126-9." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/S2255-4971(15)30126-9.</a> PMID: 27047848; PMCID: PMC4799471.
Open DOI Search in Google Scholar Back to article
Franchi A. Epidemiology and classification of bone tumors. Clin Cases Miner Bone Metab. 2012 May;9(2):92–95. Epub 2012 Sep 30. PMID: 23087718; PMCID: PMC3476517.
Search in Google Scholar Back to article
Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, Juergens H. Ewing's sarcoma family of tumors: Current management. Oncologist. 2006 May;11(5):503–519. doi:<a href="https://doi.org/10.1634/theoncologist.11-5-503." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1634/theoncologist.11-5-503.</a> PMID: 16720851.
Open DOI Search in Google Scholar Back to article
Jedlicka P. Ewing sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions. Int J Clin Exp Pathol. 2010 Mar 19;3(4):338–347. PMID: 20490326; PMCID: PMC2872742.
Search in Google Scholar Back to article
Miser JS, Goldsby RE, Chen Z, Krailo MD, Tarbell NJ, Link MP, et al. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: Evaluation of increasing the dose intensity of chemotherapy—A report from the Children's Oncology Group. Pediatr Blood Cancer. 2007 Dec;49(7):894–900. doi:<a href="https://doi.org/10.1002/pbc.21233." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/pbc.21233.</a> PMID: 17584910.
Open DOI Search in Google Scholar Back to article
Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, et al. ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl. 4):iv79–iv95. doi:<a href="https://doi.org/10.1093/annonc/mdy310." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/annonc/mdy310.</a> PMID: 30285218.
Open DOI Search in Google Scholar Back to article
Bacci G, Boriani S, Balladelli A, Barbieri E, Longhi A, Alberghini M, et al. Treatment of nonmetastatic Ewing's sarcoma family tumors of the spine and sacrum: The experience from a single institution. Eur Spine J. 2009 Aug;18(8):1091–1095. doi:<a href="https://doi.org/10.1007/s00586-009-0921-0." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s00586-009-0921-0.</a> Epub 2009 Mar 11. PMID: 19277725; PMCID: PMC2899506.
Open DOI Search in Google Scholar Back to article
Serlo J, Helenius I, Vettenranta K, Perkkiö M, Riikonen P, Sampo M, Tarkkanen M. Surgically treated patients with axial and peripheral Ewing's sarcoma family of tumours: A population based study in Finland during 1990–2009. Eur J Surg Oncol. 2015 Jul;41(7):893–898. doi:<a href="https://doi.org/10.1016/j.ejso.2015.02.010." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ejso.2015.02.010.</a> Epub 2015 Mar 19. PMID: 25817983.
Open DOI Search in Google Scholar Back to article
Rodríguez-Galindo C, Liu T, Krasin MJ, Wu J, Billups CA, Daw NC, et al. Analysis of prognostic factors in Ewing sarcoma family of tumors: Review of St. Jude Children's Research Hospital studies. Cancer. 2007 Jul 15;110(2):375–384. doi:<a href="https://doi.org/10.1002/cncr.22821." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/cncr.22821.</a> PMID: 17569105.
Open DOI Search in Google Scholar Back to article
Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, et al. The Ewing family of tumors—A subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med. 1994 Aug 4;331(5):294–299. doi:<a href="https://doi.org/10.1056/NEJM199408043310503." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1056/NEJM199408043310503.</a> PMID: 8022439.
Open DOI Search in Google Scholar Back to article
Denny CT. Gene rearrangements in Ewing's sarcoma. Cancer Invest. 1996;14(1):83–88. doi:<a href="https://doi.org/10.3109/07357909609018438." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3109/07357909609018438.</a> PMID: 8597892.
Open DOI Search in Google Scholar Back to article
Li S, Siegal GP. Small cell tumors of bone. Adv Anat Pathol. 2010 Jan;17(1):1–11. doi:<a href="https://doi.org/10.1097/PAP.0b013e3181bb6b9c." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1097/PAP.0b013e3181bb6b9c.</a> PMID: 20032633.
Open DOI Search in Google Scholar Back to article
Ross KA, Smyth NA, Murawski CD, Kennedy JG. The biology of Ewing sarcoma. ISRN Oncol. 2013;2013:759725. doi:<a href="https://doi.org/10.1155/2013/759725." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1155/2013/759725.</a> Epub 2013 Jan 10. PMID: 23346417; PMCID: PMC3549336.
Open DOI Search in Google Scholar Back to article
Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell. 2007 May;11(5):421–429. doi:<a href="https://doi.org/10.1016/j.ccr.2007.02.027." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ccr.2007.02.027.</a> PMID: 17482132.
Open DOI Search in Google Scholar Back to article
Toomey EC, Schiffman JD, Lessnick SL. Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene. 2010 Aug 12;29(32):4504–4516. doi:<a href="https://doi.org/10.1038/onc.2010.205." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/onc.2010.205.</a> Epub 2010 Jun 14. PMID: 20543858; PMCID: PMC3555143.
Open DOI Search in Google Scholar Back to article
Grünewald TG, Bernard V, Gilardi-Hebenstreit P, Raynal V, Surdez D, Aynaud MM, et al. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. Nat Genet. 2015 Sep;47(9):1073–1078. doi:<a href="https://doi.org/10.1038/ng.3363." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/ng.3363.</a> Epub 2015 Jul 27. PMID: 26214589; PMCID: PMC4591073.
Open DOI Search in Google Scholar Back to article
J.A. Ludwig, N. Federman, P. Anderson, M.E. Macy, L.E. Davis, R.F. Riedel et al., Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma. Annals of Oncol. 2020;31(suppl_4):S914–S933. doi:<a href="https://doi.org/10.1016/annonc/annonc288." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/annonc/annonc288.</a>
Open DOI Search in Google Scholar Back to article
Cidre-Aranaz F, Alonso J. EWS/FLI1 Target genes and therapeutic opportunities in Ewing sarcoma. Front Oncol. 2015 Jul 20;5:162. doi:<a href="https://doi.org/10.3389/fonc.2015.00162." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3389/fonc.2015.00162.</a> PMID: 26258070; PMCID: PMC4507460.
Open DOI Search in Google Scholar Back to article
Dunst J, Jürgens H, Sauer R, Pape H, Paulussen M, Winkelmann W, Rübe C. Radiation therapy in Ewing's sarcoma: An update of the CESS 86 trial. Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):919–930. doi:<a href="https://doi.org/10.1016/0360-3016(95)00016-r." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/0360-3016(95)00016-r.</a> PMID: 7607966.
Open DOI Search in Google Scholar Back to article
Schuck A, Ahrens S, Paulussen M, Kuhlen M, Könemann S, Rübe C, et al. Local therapy in localized Ewing tumors: Results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):168–177. doi:<a href="https://doi.org/10.1016/s0360-3016(02)03797-5." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/s0360-3016(02)03797-5.</a> PMID: 12504050.
Open DOI Search in Google Scholar Back to article
Yock TI, Krailo M, Fryer CJ, Donaldson SS, Miser JS, Chen Z, et al. Children's Oncology Group. Local control in pelvic Ewing sarcoma: Analysis from INT-0091—A report from the Children's Oncology Group. J Clin Oncol. 2006 Aug 20;24(24):3838–3843. doi:<a href="https://doi.org/10.1200/JCO.2006.05.9188." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2006.05.9188.</a> Erratum in: J Clin Oncol. 2006 Oct 20;24(30):4947. PMID: 16921035.
Open DOI Search in Google Scholar Back to article
DuBois SG, Krailo MD, Gebhardt MC, Donaldson SS, Marcus KJ, Dormans J, et al. Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: A report from the Children's Oncology Group. Cancer. 2015 Feb 1;121(3):467–475. doi:<a href="https://doi.org/10.1002/cncr.29065." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/cncr.29065.</a> Epub 2014 Sep 23. PMID: 25251206; PMCID: PMC4305012.
Open DOI Search in Google Scholar Back to article
Schuck A, Ahrens S, von Schorlemer I, Kuhlen M, Paulussen M, Hunold A, et al. Radiotherapy in Ewing tumors of the vertebrae: Treatment results and local relapse analysis of the CESS 81/86 and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1562–1567. doi:<a href="https://doi.org/10.1016/j.ijrobp.2005.05.036." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ijrobp.2005.05.036.</a> Epub 2005 Aug 30. PMID: 16137838.
Open DOI Search in Google Scholar Back to article
Indelicato DJ, Keole SR, Shahlaee AH, Shi W, Morris CG, Marcus RB Jr. Definitive radiotherapy for Ewing tumors of extremities and pelvis: Long-term disease control, limb function, and treatment toxicity. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):871–877. doi:<a href="https://doi.org/10.1016/j.ijrobp.2008.02.023." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ijrobp.2008.02.023.</a> Epub 2008 May 1. PMID: 18455323.
Open DOI Search in Google Scholar Back to article
Nesbit ME Jr, Gehan EA, Burgert EO Jr, Vietti TJ, Cangir A, Tefft M, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: A long-term follow-up of the First Intergroup study. J Clin Oncol. 1990 Oct;8(10):1664–1674. doi:<a href="https://doi.org/10.1200/JCO.1990.8.10.1664." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.1990.8.10.1664.</a> PMID: 2213103.
Open DOI Search in Google Scholar Back to article
Burgert EO Jr, Nesbit ME, Garnsey LA, Gehan EA, Herrmann J, Vietti TJ, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II. J Clin Oncol. 1990 Sep;8(9):1514–1524. doi:<a href="https://doi.org/10.1200/JCO.1990.8.9.1514." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.1990.8.9.1514.</a> PMID: 2099751.
Open DOI Search in Google Scholar Back to article
Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003 Feb 20;348(8):694–701. doi:<a href="https://doi.org/10.1056/NEJMoa020890." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1056/NEJMoa020890.</a> PMID: 12594313.
Open DOI Search in Google Scholar Back to article
Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: A Children's Oncology Group Study. J Clin Oncol. 2009 May 20;27(15):2536–2541. doi:<a href="https://doi.org/10.1200/JCO.2008.19.1478." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2008.19.1478.</a> Epub 2009 Apr 6. PMID: 19349548; PMCID: PMC2684856.
Open DOI Search in Google Scholar Back to article
Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the Children's Oncology Group. J Clin Oncol. 2012 Nov 20;30(33):4148–4154. doi:<a href="https://doi.org/10.1200/JCO.2011.41.5703." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2011.41.5703.</a> Epub 2012 Oct 22. Erratum in: J Clin Oncol. 2015 Mar 1;33(7):814. Dosage error in article text. PMID: 23091096; PMCID: PMC3494838.
Open DOI Search in Google Scholar Back to article
Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, et al. European Intergroup Cooperative Ewing's Sarcoma Study-92. Results of the EICESS-92 Study: Two randomized trials of Ewing's sarcoma treatment—Cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008 Sep 20;26(27):4385–4393. doi:<a href="https://doi.org/10.1200/JCO.2008.16.5720." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2008.16.5720.</a> PMID: 18802150.
Open DOI Search in Google Scholar Back to article
Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J, et al. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: Results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol. 2014 Aug 10;32(23):2440–2448. doi:<a href="https://doi.org/10.1200/JCO.2013.54.4833." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2013.54.4833.</a> Epub 2014 Jun 30. PMID: 24982464.
Open DOI Search in Google Scholar Back to article
Whelan J, Le Deley MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N, et al. Euro-E.W.I.N.G.99 and EWING-2008 Investigators. High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol. 2018 Sep 6;36(31):JCO2018782516. doi:<a href="https://doi.org/10.1200/JCO.2018.78.2516." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2018.78.2516.</a> Epub ahead of print. PMID: 30188789; PMCID: PMC6209090.
Open DOI Search in Google Scholar Back to article
https://clinicaltrials.gov/
Search in Google Scholar Back to article
Ginsberg JP, Goodman P, Leisenring W, Ness KK, Meyers PA, Wolden SL, et al. Long-term survivors of childhood Ewing sarcoma: Report from the childhood cancer survivor study. J Natl Cancer Inst. 2010 Aug 18;102(16):1272–1283. doi:<a href="https://doi.org/10.1093/jnci/djq278." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/jnci/djq278.</a> Epub 2010 Jul 23. PMID: 20656964; PMCID: PMC2948841.
Open DOI Search in Google Scholar Back to article
Eiser C. Assessment of health-related quality of life after bone cancer in young people: Easier said than done. Eur J Cancer. 2009 Jul;45(10):1744–1747. doi:<a href="https://doi.org/10.1016/j.ejca.2009.02.025." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ejca.2009.02.025.</a> Epub 2009 Mar 25. PMID: 19327986.
Open DOI Search in Google Scholar Back to article
Hobusch GM, Lang N, Schuh R, Windhager R, Hofstaetter JG. Do patients with Ewing's sarcoma continue with sports activities after limb salvage surgery of the lower extremity? Clin Orthop Relat Res. 2015 Mar;473(3):839–846. doi:<a href="https://doi.org/10.1007/s11999-014-3622-x." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s11999-014-3622-x.</a> PMID: 24748070; PMCID: PMC4317429.
Open DOI Search in Google Scholar Back to article
Groundland JS, Ambler SB, Houskamp LD, Orriola JJ, Binitie OT, Letson GD. Surgical and functional outcomes after limb-preservation surgery for tumor in pediatric patients: A systematic review. JBJS Rev. 2016 Feb9;4(2):01874474-201602000-00002. doi:<a href="https://doi.org/10.2106/JBJS.RVW.O.00013." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.2106/JBJS.RVW.O.00013.</a> PMID: 27490132.
Open DOI Search in Google Scholar Back to article
Peccatori FA, Azim HA Jr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, Pentheroudakis G, ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24(Suppl 6):vi160–170. doi:<a href="https://doi.org/10.1093/annonc/mdt199." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/annonc/mdt199.</a> Epub 2013 Jun 27. PMID: 23813932.
Open DOI Search in Google Scholar Back to article
Romao RL, Lorenzo AJ. Fertility preservation options for children and adolescents with cancer. Can Urol Assoc J. 2017 Jan–Feb;11(1–2, Suppl 1):S97–S102. doi:<a href="https://doi.org/10.5489/cuaj.4410." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.5489/cuaj.4410.</a> PMID: 28265333; PMCID: PMC5332250.
Open DOI Search in Google Scholar Back to article
Chen H, Xiao L, Li J, Cui L, Huang W. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev. 2019 Mar 3;3(3):CD008018. doi:<a href="https://doi.org/10.1002/14651858.CD008018.pub3." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/14651858.CD008018.pub3.</a> PMID: 30827035; PMCID: PMC6397718.
Open DOI Search in Google Scholar Back to article
Kyriazoglou A, Tsironis G, Liontos M, Papakosta A, Mahaira L, Thomakos N, et al., Ewing's sarcoma of the cervix: A case report of an unusual diagnosis in pregnancy treated with surgery, adjuvant VIDE and radiotherapy. Oncol Lett. 2019 Jun;17(6):5529–5535. doi:<a href="https://doi.org/10.3892/ol.2019.10267." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3892/ol.2019.10267.</a> Epub 2019 Apr 18. PMID: 31186774; PMCID: PMC6507342.
Open DOI Search in Google Scholar Back to article
Rodriguez-Galindo C, Billups CA, Kun LE, Rao BN, et al. Survival after recurrence of Ewing tumors: The St Jude Children's Research Hospital experience, 1979–1999. Cancer. 2002 Jan 15;94(2):561–569. doi:<a href="https://doi.org/10.1002/cncr.10192." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/cncr.10192.</a> PMID: 11900241.
Open DOI Search in Google Scholar Back to article
Bacci G, Ferrari S, Longhi A, Donati D, De Paolis M, Forni C, et al. Therapy and survival after recurrence of Ewing's tumors: The Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol. 2003 Nov;14(11):1654–1659. doi:<a href="https://doi.org/10.1093/annonc/mdg457." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/annonc/mdg457.</a> PMID: 14581274.
Open DOI Search in Google Scholar Back to article
Robinson SI, Ahmed SK, Okuno SH, Arndt CA, Rose PS, Laack NN. Clinical outcomes of adult patients with relapsed Ewing sarcoma: A 30-year single-institution experience. Am J Clin Oncol. 2014 Dec;37(6):585–591. doi:<a href="https://doi.org/10.1097/COC.0b013e318281d6ab." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1097/COC.0b013e318281d6ab.</a> PMID: 23466580.
Open DOI Search in Google Scholar Back to article
Navid F, Billups C, Liu T, Krasin MJ, Rodriguez-Galindo C. Second cancers in patients with the Ewing sarcoma family of tumours. Eur J Cancer. 2008 May;44(7):983–991. doi:<a href="https://doi.org/10.1016/j.ejca.2008.02.027." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ejca.2008.02.027.</a> Epub 2008 Mar 18. PMID: 18353632; PMCID: PMC2423466.
Open DOI Search in Google Scholar Back to article
Rodriguez-Galindo C, Poquette CA, Marina NM, Head DR, Cain A, et al. Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors. J Pediatr Hematol Oncol. 2000 Jul–Aug;22(4):321–329. doi:<a href="https://doi.org/10.1097/00043426-200007000-00008." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1097/00043426-200007000-00008.</a> PMID: 10959902.
Open DOI Search in Google Scholar Back to article
Anderson P, Kopp L, Anderson N, Cornelius K, Herzog C, Hughes D, Huh W. Novel bone cancer drugs: Investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opin Investig Drugs. 2008 Nov;17(11):1703–1715. doi:<a href="https://doi.org/10.1517/13543784.17.11.1703." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1517/13543784.17.11.1703.</a> PMID: 18922107.
Open DOI Search in Google Scholar Back to article
Wagner LM, McAllister N, Goldsby RE, Rausen AR, McNall-Knapp RY, McCarville MB, Albritton K. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007 Feb;48(2):132–139. doi:<a href="https://doi.org/10.1002/pbc.20697." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/pbc.20697.</a> PMID: 16317751.
Open DOI Search in Google Scholar Back to article
Raciborska A, Bilska K, Drabko K, Chaber R, Pogorzala M, Wyrobek E, et al. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer. 2013 Oct;60(10):1621–1625. doi:<a href="https://doi.org/10.1002/pbc.24621." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/pbc.24621.</a> Epub 2013 Jun 15. PMID: 23776128.
Open DOI Search in Google Scholar Back to article
Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP, Meyers PA. Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan-Kettering experience. Pediatr Blood Cancer. 2009 Dec;53(6):1029–1034. doi:<a href="https://doi.org/10.1002/pbc.22206." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/pbc.22206.</a> PMID: 19637327.
Open DOI Search in Google Scholar Back to article
Palmerini E, Jones RL, Setola E, Picci P, Marchesi E, Luksch R, et al. Irinotecan and temozolomide in recurrent Ewing sarcoma: An analysis in 51 adult and pediatric patients. Acta Oncol. 2018 Jul;57(7):958–964. doi:<a href="https://doi.org/10.1080/0284186X.2018.1449250." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1080/0284186X.2018.1449250.</a> Epub 2018 Mar 13. PMID: 29533113.
Open DOI Search in Google Scholar Back to article
Büyükkapu Bay S, Kebudi R, Görgün O, Zülfikar B, Darendeliler E, Çakır FB. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience. J Oncol Pharm Pract. 2019 Sep;25(6):1343–1348. doi:<a href="https://doi.org/10.1177/1078155218790798." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1177/1078155218790798.</a> Epub 2018 Aug 6. PMID: 30080131.
Open DOI Search in Google Scholar Back to article
Kurucu N, Sari N, Ilhan IE. Irinotecan and temozolamide treatment for relapsed Ewing sarcoma: A single-center experience and review of the literature. Pediatr Hematol Oncol. 2015 Feb;32(1):50–59. doi:<a href="https://doi.org/10.3109/08880018.2014.954070." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3109/08880018.2014.954070.</a> Epub 2014 Sep 24. PMID: 25252096.
Open DOI Search in Google Scholar Back to article
Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, Ingle AM, Blaney SM, Adamson PC. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Apr;54(4):538–545. doi:<a href="https://doi.org/10.1002/pbc.22407." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/pbc.22407.</a> PMID: 20049936; PMCID: PMC3074342.
Open DOI Search in Google Scholar Back to article
Wagner LM. Fifteen years of irinotecan therapy for pediatric sarcoma: Where to next? Clin Sarcoma Res. 2015 Aug 28;5:20. doi:<a href="https://doi.org/10.1186/s13569-015-0035-x." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1186/s13569-015-0035-x.</a> PMID: 26322224; PMCID: PMC4552408.
Open DOI Search in Google Scholar Back to article
Wagner LM, Crews KR, Iacono LC, Houghton PJ, Fuller CE, McCarville MB, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res. 2004 Feb 1;10(3):840–848. doi:<a href="https://doi.org/10.1158/1078-0432.ccr-03-0175." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/1078-0432.ccr-03-0175.</a> PMID: 14871959.
Open DOI Search in Google Scholar Back to article
Rapkin L, Qayed M, Brill P, Martin M, Clark D, George BA, et al. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer. 2012 Nov;59(5):854–58. doi:<a href="https://doi.org/10.1002/pbc.24101." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/pbc.24101.</a> Epub 2012 Feb 2. PMID: 22302783.
Open DOI Search in Google Scholar Back to article
Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, Daw NC. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008 Jul 15;113(2):419–425. doi:<a href="https://doi.org/10.1002/cncr.23586." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/cncr.23586.</a> PMID: 18484657.
Open DOI Search in Google Scholar Back to article
Mora J, Cruz CO, Parareda A, de Torres C. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol. 2009 Oct;31(10):723–729. doi:<a href="https://doi.org/10.1097/MPH.0b013e3181b2598c." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1097/MPH.0b013e3181b2598c.</a> PMID: 19727011.
Open DOI Search in Google Scholar Back to article
Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: The Children's Cancer Group (CCG) experience. Pediatr Blood Cancer. 2005 Apr;44(4):338–347. doi:<a href="https://doi.org/10.1002/pbc.20227." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/pbc.20227.</a> PMID: 15503297.
Open DOI Search in Google Scholar Back to article
Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, et al. Ifosfamide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987 Aug;5(8):1191–1198. doi:<a href="https://doi.org/10.1200/JCO.1987.5.8.1191." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.1987.5.8.1191.</a> PMID: 3114435.
Open DOI Search in Google Scholar Back to article
Nardo M, Zambrano EM, Vicentini MF, Toloi D, Camargo VP, Feher O, Munhoz R. 5294—Efficacy of second line treatment with etoposide and ifosfamide in adult patients with advanced Ewing sarcoma family tumors. Annals of Oncol. 2017;28 (Suppl_5):v521–v538. doi:<a href="https://doi.org/10.1093/annonc/mdx387." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/annonc/mdx387.</a>
Open DOI Search in Google Scholar Back to article
Kung FH, Pratt CB, Vega RA, Jaffe N, Strother D, Schwenn M, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer. 1993 Mar 1;71(5):1898–1903. doi:<a href="https://doi.org/10.1002/1097-0142(19930301)71:5" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/1097-0142(19930301)71:5</a><1898::aidcncr2820710529>3.0.co;2-q. PMID: 8448755.
Open DOI Search in Google Scholar Back to article
Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jürgens H. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer. 2006 Nov;47(6):795–800. doi:<a href="https://doi.org/10.1002/pbc.20719." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/pbc.20719.</a> PMID: 16411206.
Open DOI Search in Google Scholar Back to article
Saylors RL III, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, et al., Pediatric Oncology Group. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol. 2001 Aug 1;19(15):3463–3469. doi:<a href="https://doi.org/10.1200/JCO.2001.19.15.3463." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2001.19.15.3463.</a> PMID: 11481351.
Open DOI Search in Google Scholar Back to article
Farhat R, Raad R, Khoury NJ, Feghaly J, Eid T, Muwakkit S, et al. Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed Ewing sarcoma at a single institution. J Pediatr Hematol Oncol. 2013 Jul;35(5):356–360. doi:<a href="https://doi.org/10.1097/MPH.0b013e318270a343." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1097/MPH.0b013e318270a343.</a> PMID: 23042020.
Open DOI Search in Google Scholar Back to article
Bernstein ML, Devidas M, Lafreniere D, Souid AK, Meyers PA, Gebhardt M, et al. Pediatric Oncology Group; Children's Cancer Group Phase II Study 9457; Children's Oncology Group. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457—A report from the Children's Oncology Group. J Clin Oncol. 2006 Jan 1;24(1):152–159. doi:<a href="https://doi.org/10.1200/JCO.2005.02.1717." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2005.02.1717.</a> PMID: 16382125.
Open DOI Search in Google Scholar Back to article
Kebudi R, Cakir FB, Gorgun O, Agaoglu FY, Darendeliler E. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive Ewing sarcoma family tumors. Pediatr Hematol Oncol. 2013 Apr;30(3):170–77. doi:<a href="https://doi.org/10.3109/08880018.2013.767868." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3109/08880018.2013.767868.</a> PMID: 23484903.
Open DOI Search in Google Scholar Back to article
Magnan H, Goodbody CM, Riedel E, Pratilas CA, Wexler LH, Chou AJ. Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. Pediatr Blood Cancer. 2015 Apr;62(4):594–597. doi:<a href="https://doi.org/10.1002/pbc.25373." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/pbc.25373.</a> Epub 2015 Jan 28. PMID: 25630954; PMCID: PMC4474186.
Open DOI Search in Google Scholar Back to article
Ferrari S, del Prever AB, Palmerini E, Staals E, Berta M, Balladelli A, et al. Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatr Blood Cancer. 2009 May;52(5):581–584. doi:<a href="https://doi.org/10.1002/pbc.21917." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/pbc.21917.</a> PMID: 19142994.
Open DOI Search in Google Scholar Back to article
Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS. High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies—Dose-response and schedule dependence. J Clin Oncol. 1997 Jun;15(6):2378–2384. doi:<a href="https://doi.org/10.1200/JCO.1997.15.6.2378." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.1997.15.6.2378.</a> PMID: 9196153.
Open DOI Search in Google Scholar Back to article
McCabe MG, Moroz V, Khan M, Dirksen U, Evans A, Fenwick N, et al., Euro Ewing Consortium. Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. J Clin Oncol. 2019 37(15_suppl):11007.
Search in Google Scholar Back to article
McCabe MG, Kirton L, Khan M, Fenwick N, Dirksen U, Gaspar N, et al. Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). J Clin Oncol. 2020 38(15_suppl):11502.
Search in Google Scholar Back to article
McTiernan A, Driver D, Michelagnoli MP, Kilby AM, Whelan JS. High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours. Ann Oncol. 2006 Aug;17(8):1301–1305. doi:<a href="https://doi.org/10.1093/annonc/mdl108." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/annonc/mdl108.</a> Epub 2006 Jun 16. PMID: 16782749.
Open DOI Search in Google Scholar Back to article
Al-Faris N, Al Harbi T, Goia C, Pappo A, Doyle J, Gassas A. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma? Pediatr Blood Cancer. 2007 Aug;49(2):190–195. doi:<a href="https://doi.org/10.1002/pbc.21140." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/pbc.21140.</a> PMID: 17262797.
Open DOI Search in Google Scholar Back to article
Rasper M, Jabar S, Ranft A, Jürgens H, Amler S, Dirksen U. The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatr Blood Cancer. 2014 Aug;61(8):1382–1386. doi:<a href="https://doi.org/10.1002/pbc.25042." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/pbc.25042.</a> Epub 2014 Apr 11. PMID: 24729428.
Open DOI Search in Google Scholar Back to article
Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol. 2005 Jul 1;23(19):4354–4362. doi:<a href="https://doi.org/10.1200/JCO.2005.05.105." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2005.05.105.</a> Epub 2005 Mar 21. PMID: 15781881.
Open DOI Search in Google Scholar Back to article
Koscielniak E, Gross-Wieltsch U, Treuner J, Winkler P, Klingebiel T, Lang P, et al. Graft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical stem-cell transplantation in a patient with relapse of metastatic disease. J Clin Oncol. 2005 Jan 1;23(1):242–244. doi:<a href="https://doi.org/10.1200/JCO.2005.05.940." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2005.05.940.</a> PMID: 15625381.
Open DOI Search in Google Scholar Back to article
Demirer T, Barkholt L, Blaise D, Pedrazzoli P, Aglietta M, Carella AM, et al., EBMT Solid Tumors Working Party. Transplantation of allogeneic hematopoietic stem cells: An emerging treatment modality for solid tumors. Nat Clin Pract Oncol. 2008 May;5(5):256–67. doi:<a href="https://doi.org/10.1038/ncponc1104." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/ncponc1104.</a> Epub 2008 Apr 8. PMID: 18398414.
Open DOI Search in Google Scholar Back to article
Hale GA. Autologous hematopoietic stem cell transplantation for pediatric solid tumors. Expert Rev Anticancer Ther. 2005 Oct;5(5):835–846. doi:<a href="https://doi.org/10.1586/14737140.5.5.835." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1586/14737140.5.5.835.</a> PMID: 16221053.
Open DOI Search in Google Scholar Back to article
Kasper B, Lehnert T, Bernd L, Mechtersheimer G, Goldschmidt H, Ho AD, Egerer G. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant. 2004 Jul;34(1):37–41. doi:<a href="https://doi.org/10.1038/sj.bmt.1704520." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/sj.bmt.1704520.</a> PMID: 15170176.
Open DOI Search in Google Scholar Back to article
Baird K, Fry TJ, Steinberg SM, Bishop MR, Fowler DH, Delbrook CP, et al. Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas. Biol Blood Marrow Transplant. 2012 May;18(5):698–707. doi:<a href="https://doi.org/10.1016/j.bbmt.2011.08.020." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.bbmt.2011.08.020.</a> Epub 2011 Sep 5. PMID: 21896345; PMCID: PMC3262116.
Open DOI Search in Google Scholar Back to article
Drabko K, Raciborska A, Bilska K, Styczynski J, Ussowicz M, Choma M, et al. Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma. Bone Marrow Transplant. 2012 Dec;47(12):1530–1534. doi:<a href="https://doi.org/10.1038/bmt.2012.78." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/bmt.2012.78.</a> Epub 2012 May 21. PMID: 22609883.
Open DOI Search in Google Scholar Back to article
Reed DR, Hayashi M, Wagner L, Binitie O, Steppan DA, Brohl AS, et al. Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer. 2017 Jun 15;123(12):2206–2218. doi:<a href="https://doi.org/10.1002/cncr.30589." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/cncr.30589.</a> Epub 2017 Mar 21. PMID: 28323337; PMCID: PMC5485018.
Open DOI Search in Google Scholar Back to article
Leemann-Zakaryan RP, Pahlich S, Sedda MJ, Quero L, Grossenbacher D, Gehring H. Dynamic subcellular localization of the Ewing sarcoma proto-oncoprotein and its association with and stabilization of microtubules. J Mol Biol. 2009 Feb 13;386(1):1–13. doi:<a href="https://doi.org/10.1016/j.jmb.2008.12.039." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.jmb.2008.12.039.</a> Epub 2008 Dec 24. PMID: 19133275.
Open DOI Search in Google Scholar Back to article
Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, et al. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013 Aug;60(8):1325–1332. doi:<a href="https://doi.org/10.1002/pbc.24517." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/pbc.24517.</a> Epub 2013 Mar 28. PMID: 23553917; PMCID: PMC4263960.
Open DOI Search in Google Scholar Back to article
Wagner LM, Yin H, Eaves D, Currier M, Cripe TP. Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma. Pediatr Blood Cancer. 2014 Nov;61(11):2096–2098. doi:<a href="https://doi.org/10.1002/pbc.25062." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/pbc.25062.</a> Epub 2014 Apr 19. PMID: 24753077.
Open DOI Search in Google Scholar Back to article
Le Cesne A, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, et al. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur J Cancer. 2012 Nov;48(16):3036–3044. doi:<a href="https://doi.org/10.1016/j.ejca.2012.05.012." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ejca.2012.05.012.</a> Epub 2012 Jun 29. PMID: 22749255.
Open DOI Search in Google Scholar Back to article
Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, et al. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children's Oncology Group. Eur J Cancer. 2012 Mar;48(4):579–585. doi:<a href="https://doi.org/10.1016/j.ejca.2011.09.027." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ejca.2011.09.027.</a> Epub 2011 Nov 14. PMID: 22088484.
Open DOI Search in Google Scholar Back to article
Romano M, Frapolli R, Zangarini M, Bello E, Porcu L, Galmarini CM, et al. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104). Int J Cancer. 2013 Nov;133(9):2024–2033. doi:<a href="https://doi.org/10.1002/ijc.28213." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/ijc.28213.</a> Epub 2013 May 25. PMID: 23588839.
Open DOI Search in Google Scholar Back to article
Subbiah V, Kumar Sankhala K, Ratan R, Sanz Garcia E, Boni V, Gil T, et al. Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study. J Clin Oncol. 2018;36(15_suppl):11519.
Search in Google Scholar Back to article
Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 2012 Apr 1;72(7):1608–1613. doi:<a href="https://doi.org/10.1158/0008-5472.CAN-11-3648." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/0008-5472.CAN-11-3648.</a> Epub 2012 Jan 27. PMID: 22287547; PMCID: PMC3319786.
Open DOI Search in Google Scholar Back to article
Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012 Mar 28;483(7391):570–575. doi:<a href="https://doi.org/10.1038/nature11005." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/nature11005.</a> PMID: 22460902; PMCID: PMC3349233.
Open DOI Search in Google Scholar Back to article
Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014 Nov 5;14:813. doi:<a href="https://doi.org/10.1186/1471-2407-14-813." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1186/1471-2407-14-813.</a> PMID: 25374341; PMCID: PMC4230717.
Open DOI Search in Google Scholar Back to article
Vormoor B, Schlosser YT, Blair H, Sharma A, Wilkinson S, Newell DR, Curtin N. Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2. Oncotarget. 2017 Sep 28;8(69):113418–113430. doi:<a href="https://doi.org/10.18632/oncotarget.21300." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.18632/oncotarget.21300.</a> PMID: 29371919; PMCID: PMC5768336.
Open DOI Search in Google Scholar Back to article
Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, et al. Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep. 2014 Nov 6;9(3):829–841. doi:<a href="https://doi.org/10.1016/j.celrep.2014.09.028." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.celrep.2014.09.028.</a> Epub 2014 Oct 23. PMID: 25437539; PMCID: PMC4386669.
Open DOI Search in Google Scholar Back to article
Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, et al. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res. 2015 Feb 15;21(4):819–832. doi:<a href="https://doi.org/10.1158/1078-0432.CCR-14-2572." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/1078-0432.CCR-14-2572.</a> Epub 2014 Dec 10. Erratum in: Clin Cancer Res. 2017 Feb 15;23 (4):1118–1119. PMID: 25500058; PMCID: PMC4587665.
Open DOI Search in Google Scholar Back to article
Wilcoxen KM, Brooks DG, Tiruchinapalli D, Anderson N, Donaldson R, McIver Nivens, et al. The PARP inhibitor niraparib demonstrates synergy with chemotherapy in treatment of patient derived Ewing's sarcoma tumorGraft models [abstract]. In Proceedings of the AACR-NCI-EORTC International Conference: Molecular targets and cancer therapeutics; 2013 Oct 19–23; Boston, MA: AACR; Mol Cancer Ther. 2013;12(11 Suppl):Abstract nr A258.
Search in Google Scholar Back to article
Gill SJ, Travers J, Pshenichnaya I, Kogera FA, Barthorpe S, Mironenko T, et al. Combinations of PARP inhibitors with temozolomide drive PARP1 trapping and apoptosis in Ewing's sarcoma. PLoS One. 2015 Oct 27;10(10):e0140988. doi:<a href="https://doi.org/10.1371/journal.pone.0140988." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1371/journal.pone.0140988.</a> PMID: 26505995; PMCID: PMC4624427.
Open DOI Search in Google Scholar Back to article
Iniguez AB, Stolte B, Wang EJ, Conway AS, Alexe G, Dharia NV, et al. EWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma. Cancer Cell. 2018 Feb 12;33(2):202–216.e6. doi:<a href="https://doi.org/10.1016/j.ccell.2017.12.009." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ccell.2017.12.009.</a> Epub 2018 Jan 18. PMID: 29358035; PMCID: PMC5846483.
Open DOI Search in Google Scholar Back to article
Tang F, Choy E, Tu C, Hornicek F, Duan Z. Therapeutic applications of histone deacetylase inhibitors in sarcoma. Cancer Treat Rev. 2017 Sep;59:33–45. doi:<a href="https://doi.org/10.1016/j.ctrv.2017.06.006." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ctrv.2017.06.006.</a> Epub 2017 Jul 6. PMID: 28732326; PMCID: PMC5581728.
Open DOI Search in Google Scholar Back to article
Sampson ER, Amin V, Schwarz EM, O’Keefe RJ, Rosier RN. The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy. J Orthop Res. 2011 Apr;29(4):623–32. doi:<a href="https://doi.org/10.1002/jor.21274." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/jor.21274.</a> Epub 2010 Oct 18. PMID: 20957741.
Open DOI Search in Google Scholar Back to article
Heinicke U, Kupka J, Fulda S. JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis. Oncotarget. 2015 Nov 10;6(35):37836–37851. doi:<a href="https://doi.org/10.18632/oncotarget.6097." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.18632/oncotarget.6097.</a> PMID: 26473375; PMCID: PMC4741969.
Open DOI Search in Google Scholar Back to article
Heinicke U, Fulda S. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA. Cancer Lett. 2014 Aug 28;351(1):50–58. doi:<a href="https://doi.org/10.1016/j.canlet.2014.04.021." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.canlet.2014.04.021.</a> Epub 2014 May 6. PMID: 24814395.
Open DOI Search in Google Scholar Back to article
Sampson VB, Vetter NS, Kamara DF, Collier AB, Gresh RC, Kolb EA. Vorinostat enhances cytotoxicity of SN-38 and temozolomide in Ewing sarcoma cells and activates STAT3/AKT/MAPK pathways. PLoS One. 2015 Nov 16;10(11):e0142704. doi:<a href="https://doi.org/10.1371/journal.pone.0142704." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1371/journal.pone.0142704.</a> PMID: 26571493; PMCID: PMC4646493.
Open DOI Search in Google Scholar Back to article
Unland R, Clemens D, Heinicke U, Potratz JC, Hotfilder M, Fulda S, et al. Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines. Anticancer Drugs. 2015 Sep;26(8):843–851. doi:<a href="https://doi.org/10.1097/CAD.0000000000000256." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1097/CAD.0000000000000256.</a> PMID: 26053276.
Open DOI Search in Google Scholar Back to article
Schonn I, Hennesen J, Dartsch DC. Ku70 and Rad51 vary in their importance for the repair of doxorubicin-versus etoposide-induced DNA damage. Apoptosis. 2011 Apr;16(4):359–369. doi:<a href="https://doi.org/10.1007/s10495-010-0564-y." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s10495-010-0564-y.</a> PMID: 21107697.
Open DOI Search in Google Scholar Back to article
Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, et al. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res. 2009 May 15;15(10):3472–83. doi:<a href="https://doi.org/10.1158/1078-0432.CCR-08-2714." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/1078-0432.CCR-08-2714.</a> Epub 2009 May 5. Erratum in Clin Cancer Res. 2015 Apr 1;21(7):1774–1775. PMID: 19417021.
Open DOI Search in Google Scholar Back to article
Becker M, Graf C, Tonak M, Radsak MP, Bopp T, Bals R, et al. Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents. Oncol Lett. 2016 Aug;12(2):1257–1264. doi:<a href="https://doi.org/10.3892/ol.2016.4784." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3892/ol.2016.4784.</a> Epub 2016 Jun 24. PMID: 27446424; PMCID: PMC4950181.
Open DOI Search in Google Scholar Back to article
Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X, et al. Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells. Cancer Chemother Pharmacol. 2011 Feb;67(2):439–446. doi:<a href="https://doi.org/10.1007/s00280-010-1344-7." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s00280-010-1344-7.</a> Epub 2010 May 12. PMID: 20461381.
Open DOI Search in Google Scholar Back to article
Capobianco E, Mora A, La Sala D, Roberti A, Zaki N, et al. Separate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell line. PLoS One. 2014 Apr 22;9(4):e95596. doi:<a href="https://doi.org/10.1371/journal.pone.0095596." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1371/journal.pone.0095596.</a> PMID: 24756038; PMCID: PMC3995708.
Open DOI Search in Google Scholar Back to article
Nakamura T, Matsumine A, Kawai A, Araki N, Goto T, Yonemoto T, et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer. 2016 May 1;122(9):1408–1416. doi:<a href="https://doi.org/10.1002/cncr.29961." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/cncr.29961.</a> Epub 2016 Mar 11. PMID: 26970174; PMCID: PMC5069581.
Open DOI Search in Google Scholar Back to article
Loganathan SN, Tang N, Fleming JT, Ma Y, Guo Y, Borinstein SC, et al. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Oncotarget. 2016 Jul 12;7(28):43504–43517. doi:<a href="https://doi.org/10.18632/oncotarget.9762." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.18632/oncotarget.9762.</a> PMID: 27259270; PMCID: PMC5190040.
Open DOI Search in Google Scholar Back to article
Hensel T, Giorgi C, Schmidt O, Calzada-Wack J, Neff F, Buch T, Niggli FK, et al. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Oncotarget. 2016 Jan 12;7(2):1451–1463. doi:<a href="https://doi.org/10.18632/oncotarget.6385." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.18632/oncotarget.6385.</a> PMID: 26623725; PMCID: PMC4811472.
Open DOI Search in Google Scholar Back to article
Pedersen MT, Helin K. Histone demethylases in development and disease. Trends Cell Biol. 2010 Nov;20(11):662–671. doi:<a href="https://doi.org/10.1016/j.tcb.2010.08.011." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.tcb.2010.08.011.</a> Epub 2010 Sep 20. PMID: 20863703.
Open DOI Search in Google Scholar Back to article
Chen Y, Jie W, Yan W, Zhou K, Xiao Y. Lysine-specific histone demethylase 1 (LSD1): A potential molecular target for tumor therapy. Crit Rev Eukaryot Gene Expr. 2012;22(1):53–59. doi:<a href="https://doi.org/10.1615/critreveukargeneexpr.v22.i1.40." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1615/critreveukargeneexpr.v22.i1.40.</a> PMID: 22339659.
Open DOI Search in Google Scholar Back to article
Theisen ER, Pishas KI, Saund RS, Lessnick SL. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting. Oncotarget. 2016 Apr 5;7(14):17616–17630. doi:<a href="https://doi.org/10.18632/oncotarget.7124." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.18632/oncotarget.7124.</a> PMID: 26848860; PMCID: PMC4951237.
Open DOI Search in Google Scholar Back to article
Spriano F, Chung EYL, Gaudio E, Tarantelli C, Cascione L, Napoli S, et al. The ETS inhibitors YK-4-279 and TK-216 are novel antilymphoma agents. Clin Cancer Res. 2019 Aug 15;25(16):5167–5176. doi:<a href="https://doi.org/10.1158/1078-0432.CCR-18-2718." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/1078-0432.CCR-18-2718.</a> Epub 2019 Jun 10. PMID: 31182435.
Open DOI Search in Google Scholar Back to article
Stega J, Noel MS, Vandell AG, Stega D, Del Priore G, Hoffman S. A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer. Invest New Drugs. 2020 Apr;38(2):392–401. doi:<a href="https://doi.org/10.1007/s10637-019-00758-8." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s10637-019-00758-8.</a> Epub 2019 Mar 30. PMID: 30929156; PMCID: PMC7066285.
Open DOI Search in Google Scholar Back to article
Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993 Dec 16;366(6456):704–707. doi:<a href="https://doi.org/10.1038/366704a0." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/366704a0.</a> PMID: 8259215.
Open DOI Search in Google Scholar Back to article
Kennedy AL, Vallurupalli M, Chen L, Crompton B, Cowley G, Vazquez F, et al. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget. 2015 Oct 6;6(30):30178–30193. doi:<a href="https://doi.org/10.18632/oncotarget.4903." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.18632/oncotarget.4903.</a> PMID: 26337082; PMCID: PMC4745789.
Open DOI Search in Google Scholar Back to article
Dowless M, Lowery CD, Shackleford T, Renschler M, Stephens J, Flack R, et al. Abemaciclib is active in preclinical models of Ewing sarcoma via multipronged regulation of cell cycle, DNA methylation, and interferon pathway signaling. Clin Cancer Res. 2018 Dec 1;24(23):6028–6039. doi:<a href="https://doi.org/10.1158/1078-0432.CCR-18-1256." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/1078-0432.CCR-18-1256.</a> Epub 2018 Aug 21. PMID: 30131386; PMCID: PMC6279561.
Open DOI Search in Google Scholar Back to article
Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993 Apr 29;362(6423):857–860. doi:<a href="https://doi.org/10.1038/362857a0." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/362857a0.</a> PMID: 8479525.
Open DOI Search in Google Scholar Back to article
Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004 Nov 24;119(5):591–602. doi:<a href="https://doi.org/10.1016/j.cell.2004.11.022." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.cell.2004.11.022.</a> PMID: 15550242.
Open DOI Search in Google Scholar Back to article
Shi D, Gu W. Dual roles of MDM2 in the regulation of p53: Ubiquitination dependent and ubiquitination independent mechanisms of MDM2 repression of p53 activity. Genes Cancer. 2012 Mar;3(3–4):240–248. doi:<a href="https://doi.org/10.1177/1947601912455199." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1177/1947601912455199.</a> PMID: 23150757; PMCID: PMC3494363.
Open DOI Search in Google Scholar Back to article
Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, et al. Nutlin-3a is a potential therapeutic for Ewing sarcoma. Clin Cancer Res. 2011 Feb 1;17(3):494–504. doi:<a href="https://doi.org/10.1158/1078-0432.CCR-10-1587." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/1078-0432.CCR-10-1587.</a> Epub 2010 Nov 23. PMID: 21098696.
Open DOI Search in Google Scholar Back to article
Wang H, Ma X, Ren S, Buolamwini JK, Yan C. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther. 2011 Jan;10(1):69–79. doi:<a href="https://doi.org/10.1158/1535-7163.MCT-10-0581." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/1535-7163.MCT-10-0581.</a> Epub 2010 Nov 12. PMID: 21075910; PMCID: PMC3058295.
Open DOI Search in Google Scholar Back to article
Depping R, von Fallois M, Landesman Y, Kosyna FK. The nuclear export inhibitor selinexor inhibits hypoxia signaling pathways and 3D spheroid growth of cancer cells. Onco Targets Ther. 2019 Oct 11;12:8387–8399. doi:<a href="https://doi.org/10.2147/OTT.S213208." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.2147/OTT.S213208.</a> PMID: 31632086; PMCID: PMC6793465.
Open DOI Search in Google Scholar Back to article
Gounder MM, Zer A, Tap WD, Salah S, Dickson MA, Gupta AA, et al. Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J Clin Oncol. 2016 Sep 10;34(26):3166–3174. doi:<a href="https://doi.org/10.1200/JCO.2016.67.6346." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2016.67.6346.</a> Epub 2016 Jul 25. Erratum in J Clin Oncol. 2017 Mar;35(7):812. PMID: 27458288; PMCID: PMC5321073.
Open DOI Search in Google Scholar Back to article
Taylor-Kashton C, Lichtensztejn D, Baloglu E, Senapedis W, Shacham S, Kauffman MG, et al. XPO1 inhibition preferentially disrupts the 3D nuclear organization of telomeres in tumor cells. J Cell Physiol. 2016 Dec;231(12):2711–2719. doi:<a href="https://doi.org/10.1002/jcp.25378." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/jcp.25378.</a> Epub 2016 Apr 8. PMID: 26991404; PMCID: PMC5111786.
Open DOI Search in Google Scholar Back to article
Nakayama R, Zhang YX, Czaplinski JT, Anatone AJ, Sicinska ET, Fletcher JA, et al. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget. 2016 Mar 29;7(13):16581–16592. doi:<a href="https://doi.org/10.18632/oncotarget.7667." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.18632/oncotarget.7667.</a> PMID: 26918731; PMCID: PMC4941336.
Open DOI Search in Google Scholar Back to article
Nair JS, Musi E, Schwartz GK. Selinexor (KPT-330) induces tumor suppression through nuclear sequestration of IκB and downregulation of survivin. Clin Cancer Res. 2017 Aug 1;23(15):4301–4311. doi:<a href="https://doi.org/10.1158/1078-0432.CCR-16-2632." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/1078-0432.CCR-16-2632.</a> Epub 2017 Mar 17. PMID: 28314790.
Open DOI Search in Google Scholar Back to article
Kashyap T, Argueta C, Aboukameel A, Unger TJ, Klebanov B, Mohammad RM, et al. Selinexor, a selective inhibitor of nuclear export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget. 2016 Nov 29;7(48):78883–78895. doi:<a href="https://doi.org/10.18632/oncotarget.12428." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.18632/oncotarget.12428.</a> PMID: 27713151; PMCID: PMC5346685.
Open DOI Search in Google Scholar Back to article
Ahmed AA, Sherman AK, Pawel BR. Expression of therapeutic targets in Ewing sarcoma family tumors. Hum Pathol. 2012 Jul;43(7):1077–1083. doi:<a href="https://doi.org/10.1016/j.humpath.2011.09.001." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.humpath.2011.09.001.</a> Epub 2011 Dec 21. PMID: 22196127.
Open DOI Search in Google Scholar Back to article
Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008 Jan 20;26(3):361–67. doi:<a href="https://doi.org/10.1200/JCO.2007.12.0345." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2007.12.0345.</a> PMID: 18202410.
Open DOI Search in Google Scholar Back to article
Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, et al. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A Children's Oncology Group Study. Pediatr Blood Cancer. 2014 May;61(5):833–839. doi:<a href="https://doi.org/10.1002/pbc.24874." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/pbc.24874.</a> Epub 2013 Nov 19. PMID: 24249672; PMCID: PMC4196713.
Open DOI Search in Google Scholar Back to article
Trucco MM, Meyer CF, Thornton KA, Shah P, Chen AR, Wilky BA, et al. A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas. Clin Sarcoma Res. 2018 Nov 5;8:21. doi:<a href="https://doi.org/10.1186/s13569-018-0107-9." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1186/s13569-018-0107-9.</a> PMID: 30410720; PMCID: PMC6217787.
Open DOI Search in Google Scholar Back to article
Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004 Aug;24(16):7275–7283. doi:<a href="https://doi.org/10.1128/MCB.24.16.7275-7283.2004." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1128/MCB.24.16.7275-7283.2004.</a> PMID: 15282325; PMCID: PMC479730.
Open DOI Search in Google Scholar Back to article
Scotlandi K, Benini S, Sarti M, Serra M, Lollini PL, Maurici D, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: A possible therapeutic target. Cancer Res. 1996 Oct 15;56(20):4570–4574. PMID: 8840962.
Search in Google Scholar Back to article
Kang HG, Jenabi JM, Liu XF, Reynolds CP, Triche TJ, Sorensen PH. Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Mol Cancer Ther. 2010 May;9(5):1396–1407. doi:<a href="https://doi.org/10.1158/1535-7163.MCT-09-0604." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/1535-7163.MCT-09-0604.</a> Epub 2010 Apr 27. PMID: 20423994.
Open DOI Search in Google Scholar Back to article
Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, Lollini PL, et al. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res. 2007 Feb 15;13(4):1322–1330. doi:<a href="https://doi.org/10.1158/1078-0432.CCR-06-1518." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/1078-0432.CCR-06-1518.</a> PMID: 17317844
Open DOI Search in Google Scholar Back to article
Scotlandi K, Benini S, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res. 1998 Sep 15;58(18):4127–4131. PMID: 9751624.
Search in Google Scholar Back to article
Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009 Dec 1;27(34):5800–5807. doi:<a href="https://doi.org/10.1200/JCO.2009.23.6745." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2009.23.6745.</a> Epub 2009 Sep 28. PMID: 19786654.
Open DOI Search in Google Scholar Back to article
Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol. 2012 May 20;30(15):1849–1856. doi:<a href="https://doi.org/10.1200/JCO.2011.37.2359." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.2011.37.2359.</a> Epub 2012 Apr 16. PMID: 22508822.
Open DOI Search in Google Scholar Back to article
Rajabi M, Mousa SA. The role of angiogenesis in cancer treatment. Biomedicines. 2017 Jun 21;5(2):34. doi:<a href="https://doi.org/10.3390/biomedicines5020034." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/biomedicines5020034.</a> PMID: 28635679; PMCID: PMC5489820.
Open DOI Search in Google Scholar Back to article
DuBois SG, Marina N, Glade-Bender J. Angiogenesis and vascular targeting in Ewing sarcoma: A review of preclinical and clinical data. Cancer. 2010 Feb 1;116(3):749–757. doi:<a href="https://doi.org/10.1002/cncr.24844." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/cncr.24844.</a> PMID: 20029966; PMCID: PMC2815027.
Open DOI Search in Google Scholar Back to article
Zhou Z, Bolontrade MF, Reddy K, Duan X, Guan H, Yu L, et al. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res. 2007 Aug 15;13(16):4867–4873. doi:<a href="https://doi.org/10.1158/1078-0432.CCR-07-0133." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/1078-0432.CCR-07-0133.</a> PMID: 17699866.
Open DOI Search in Google Scholar Back to article
Reddy K, Zhou Z, Schadler K, Jia SF, Kleinerman ES. Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels. Mol Cancer Res. 2008 Jun;6(6):929–936. doi:<a href="https://doi.org/10.1158/1541-7786.MCR-07-2189." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/1541-7786.MCR-07-2189.</a> PMID: 18567797; PMCID: PMC2441901.
Open DOI Search in Google Scholar Back to article
Potikyan G, Savene RO, Gaulden JM, France KA, Zhou Z, Kleinerman ES, et al. EWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins. Cancer Res. 2007 Jul 15;67(14):6675–6684. doi:<a href="https://doi.org/10.1158/0008-5472.CAN-06-4140." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/0008-5472.CAN-06-4140.</a> PMID: 17638877.
Open DOI Search in Google Scholar Back to article
Bukowski RM, Yasothan U, Kirkpatrick P, Pazopanib. Nat Rev Drug Discov. 2010 Jan;9(1):17–18. doi:<a href="https://doi.org/10.1038/nrd3073." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/nrd3073.</a> PMID: 20043026.
Open DOI Search in Google Scholar Back to article
van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al., EORTC Soft Tissue and Bone Sarcoma Group, PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19;379(9829):1879–1886. doi:<a href="https://doi.org/10.1016/S0140-6736(12)60651-5." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/S0140-6736(12)60651-5.</a> Epub 2012 May 16. PMID: 22595799.
Open DOI Search in Google Scholar Back to article
Alcindor T. Response of refractory Ewing sarcoma to pazopanib. Acta Oncol. 2015 Jul;54(7):1063–1064. doi:<a href="https://doi.org/10.3109/0284186X.2014.971938." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3109/0284186X.2014.971938.</a> Epub 2014 Oct 27. PMID: 25345493.
Open DOI Search in Google Scholar Back to article
Attia S, Okuno SH, Robinson SI, Webber NP, Indelicato DJ, Jones RL, et al. Clinical activity of pazopanib in metastatic extraosseous Ewing sarcoma. Rare Tumors. 2015 May 21;7(2):5992. doi:<a href="https://doi.org/10.4081/rt.2015.5992." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.4081/rt.2015.5992.</a> PMID: 26266019; PMCID: PMC4508650.
Open DOI Search in Google Scholar Back to article
Yamamoto Y, Nozawa M, Shimizu N, Minami T, Yoshimura K, Uemura H. Pazopanib for recurrent extraosseous Ewing's sarcoma of the retroperitoneum. Int J Urol. 2014 Nov;21(11):1183–1184. doi:<a href="https://doi.org/10.1111/iju.12546." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1111/iju.12546.</a> Epub 2014 Jul 8. PMID: 25040171.
Open DOI Search in Google Scholar Back to article
Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, et al. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep. 2017 Nov 21;7(1):15963. doi:<a href="https://doi.org/10.1038/s41598-017-13114-8." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/s41598-017-13114-8.</a> PMID: 29162825; PMCID: PMC5698336.
Open DOI Search in Google Scholar Back to article
Keir ST, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2012 Sep;59(3):586–588. doi:<a href="https://doi.org/10.1002/pbc.24016." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/pbc.24016.</a> Epub 2011 Dec 20. PMID: 22190407; PMCID: PMC4245051.
Open DOI Search in Google Scholar Back to article
Smith M, Kang M, Reynolds P, Gorlick R, Kolb A, Maris J, et al. Abstract LB-353: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of cabozantinib. Cancer Res. 2013 Apr 15; 73(8 Suppl.):LB-353. doi:<a href="https://doi.org/10.1158/1538-7445.AM2013-LB-353." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/1538-7445.AM2013-LB-353.</a>
Open DOI Search in Google Scholar Back to article
Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E, et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): A multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020 Mar;21(3):446–455. doi:<a href="https://doi.org/10.1016/S1470-2045(19)30825-3." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/S1470-2045(19)30825-3.</a> Epub 2020 Feb 17. PMID: 32078813.
Open DOI Search in Google Scholar Back to article
Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, et al. Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol. 2019 Jun 1;37(16):1424–1431. doi:<a href="https://doi.org/10.1200/JCO.18.02374." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.18.02374.</a> Epub 2019 Apr 23. PMID: 31013172.
Open DOI Search in Google Scholar Back to article
Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, et al., French Sarcoma Group. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: A non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019 Jan;20(1):120–133. doi:<a href="https://doi.org/10.1016/S1470-2045(18)30742-3." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/S1470-2045(18)30742-3.</a> Epub 2018 Nov 23. PMID: 30477937.
Open DOI Search in Google Scholar Back to article
Attia A, Bolejack V, Ganjoo KN, George S, Agulnik M, Rushing DA, et al. A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results. J Clin Oncol. 2017; 35(15_suppl):11005.
Search in Google Scholar Back to article
Wang HY, Chu JF, Zhang P, Wang JQ, Yan Z, Yao SN, et al. Safety and efficacy of chemotherapy combined with anlotinib plus anlotinib maintenance in Chinese patients with advanced/metastatic soft tissue sarcoma. Onco Targets Ther. 2020 Feb 19;13:1561–1568. doi:<a href="https://doi.org/10.2147/OTT.S235349." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.2147/OTT.S235349.</a> PMID: 32110053; PMCID: PMC7038775.
Open DOI Search in Google Scholar Back to article
Xu J, Xie L, Guo W, Tang X, Yang R, Yan T, et al. Anlotinib and irinotecan for advanced Ewing sarcoma after failure of standard therapy: A multicenter, two-cohort, single-arm, open label, phase Ib/II trial (NCT03416517). J Clin Oncol. 2019; 37(15_suppl):11012.
Search in Google Scholar Back to article
Das SK, Menezes ME, Bhatia S, Wang XY, Emdad L, Sarkar D, Fisher PB. Gene therapies for cancer: Strategies, challenges and successes. J Cell Physiol. 2015 Feb;230(2):259–271. doi:<a href="https://doi.org/10.1002/jcp.24791." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/jcp.24791.</a> PMID: 25196387; PMCID: PMC4363073.
Open DOI Search in Google Scholar Back to article
Rao DD, Jay C, Wang Z, Luo X, Kumar P, Eysenbach H, et al. Preclinical justification of pbi-shRNA EWS/FLI1 lipoplex (LPX) treatment for Ewing's sarcoma. Mol Ther. 2016 Aug;24(8):1412–1422. doi:<a href="https://doi.org/10.1038/mt.2016.93." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/mt.2016.93.</a> Epub 2016 May 11. PMID: 27166877; PMCID: PMC5023384.
Open DOI Search in Google Scholar Back to article
Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, et al. The genomic landscape of the Ewing sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet. 2014 Jul 10;10(7):e1004475. doi:<a href="https://doi.org/10.1371/journal.pgen.1004475." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1371/journal.pgen.1004475.</a> Erratum in PLoS Genet. 2014 Aug;10(8):e1004629. PMID: 25010205; PMCID: PMC4091782.
Open DOI Search in Google Scholar Back to article
Liu J, Zheng X, Pang X, Li L, Wang J, Yang C, Du G. Ganglioside GD3 synthase (GD3S), a novel cancer drug target. Acta Pharm Sin B. 2018 Sep;8(5):713–720. doi:<a href="https://doi.org/10.1016/j.apsb.2018.07.009." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.apsb.2018.07.009.</a> Epub 2018 Jul 25. PMID: 30245960; PMCID: PMC6147802.
Open DOI Search in Google Scholar Back to article
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020 Jan 1;38(1):1–10. doi:<a href="https://doi.org/10.1200/JCO.19.02105." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/JCO.19.02105.</a> Epub 2019 Nov 4. PMID: 31682550.
Open DOI Search in Google Scholar Back to article
Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 Nov;18(11):1493–1501. doi:<a href="https://doi.org/10.1016/S1470-2045(17)30624-1." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/S1470-2045(17)30624-1.</a> Epub 2017 Oct 4. Erratum in Lancet Oncol. 2017 Dec;18(12):e711. Erratum in Lancet Oncol. 2018 Jan;19(1):e8. PMID: 28988646.
Open DOI Search in Google Scholar Back to article
Raj S, Bui M, Gonzales R, Letson D, Antonia SJ. Impact of PDL1 expression on clinical outcomes in subtypes of sarcoma. Ann Oncol. 2014;25:iv494–iv510.
Search in Google Scholar Back to article
Machado I, López-Guerrero JA, Scotlandi K, Picci P, Llombart-Bosch A. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT). Virchows Arch. 2018 May;472(5):815–824. doi:<a href="https://doi.org/10.1007/s00428-018-2316-2." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s00428-018-2316-2.</a> Epub 2018 Feb 14. PMID: 29445891.
Open DOI Search in Google Scholar Back to article
Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014 Nov;4(11):1326–1341. doi:<a href="https://doi.org/10.1158/2159-8290.CD-13-1037." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/2159-8290.CD-13-1037.</a> Epub 2014 Sep 3. PMID: 25186949.
Open DOI Search in Google Scholar Back to article
Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, et al., St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project and the International Cancer Genome Consortium. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 2014 Nov;4(11):1342–1353. doi:<a href="https://doi.org/10.1158/2159-8290.CD-14-0622." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/2159-8290.CD-14-0622.</a> Epub 2014 Sep 15. PMID: 25223734; PMCID: PMC4264969.
Open DOI Search in Google Scholar Back to article
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013 Mar 29;339(6127):1546–1558. doi:<a href="https://doi.org/10.1126/science.1235122." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1126/science.1235122.</a> PMID: 23539594; PMCID: PMC3749880.
Open DOI Search in Google Scholar Back to article
Davis KL, Fox E, Reid JM, Liu X, Minard CG, Weigel B, Mackall, C. ADVL1412: Initial results of a phase I/II study of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumors—A COG study. J Clin Oncol. 2017 35(15_suppl):10526.
Search in Google Scholar Back to article
D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018 Mar;19(3):416–426. doi:<a href="https://doi.org/10.1016/S1470-2045(18)30006-8." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/S1470-2045(18)30006-8.</a> Epub 2018 Jan 19. PMID: 29370992; PMCID: PMC6126546.
Open DOI Search in Google Scholar Back to article
Rocchi A, Manara MC, Sciandra M, Zambelli D, Nardi F, Nicoletti G, et al. CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J Clin Invest. 2010 Mar;120(3):668–680. doi:<a href="https://doi.org/10.1172/JCI36667." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1172/JCI36667.</a> Epub 2010 Feb 8. PMID: 20197622; PMCID: PMC2827943.
Open DOI Search in Google Scholar Back to article
O’Neill AF, Dearling JL, Wang Y, Tupper T, Sun Y, Aster JC, et al. Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody. Clin Cancer Res. 2014 Feb 1;20(3):678–687. doi:<a href="https://doi.org/10.1158/1078-0432.CCR-13-1660." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/1078-0432.CCR-13-1660.</a> Epub 2013 Nov 11. PMID: 24218512; PMCID: PMC3946397.
Open DOI Search in Google Scholar Back to article
Dobrenkov K, Ostrovnaya I, Gu J, Cheung IY, Cheung NK. Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. Pediatr Blood Cancer. 2016 Oct;63(10):1780–1785. doi:<a href="https://doi.org/10.1002/pbc.26097." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/pbc.26097.</a> Epub 2016 Jun 15. PMID: 27304202; PMCID: PMC5215083.
Open DOI Search in Google Scholar Back to article
Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, et al. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer. 2012 Mar 13;106(6):1123–1133. doi:<a href="https://doi.org/10.1038/bjc.2012.57." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/bjc.2012.57.</a> Epub 2012 Feb 28. PMID: 22374462; PMCID: PMC3304425.
Open DOI Search in Google Scholar Back to article
Fisher JP, Flutter B, Wesemann F, Frosch J, Rossig C, Gustafsson K, Anderson J. Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells. Oncoimmunology. 2015 Apr 27;5(1):e1025194. doi:<a href="https://doi.org/10.1080/2162402X.2015.1025194." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1080/2162402X.2015.1025194.</a> PMID: 26942051; PMCID: PMC4760299.
Open DOI Search in Google Scholar Back to article
Lipinski M, Hirsch MR, Deagostini-Bazin H, Yamada O, Tursz T, Goridis C. Characterization of neural cell adhesion molecules (NCAM) expressed by Ewing and neuroblastoma cell lines. Int J Cancer. 1987 Jul 15;40(1):81–86. doi:<a href="https://doi.org/10.1002/ijc.2910400115." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/ijc.2910400115.</a> PMID: 3036723.
Open DOI Search in Google Scholar Back to article
Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, et al. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer. 2012 Mar 13;106(6):1123–1133. doi:<a href="https://doi.org/10.1038/bjc.2012.57." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/bjc.2012.57.</a> Epub 2012 Feb 28. PMID: 22374462; PMCID: PMC3304425.
Open DOI Search in Google Scholar Back to article
Ghisoli M, Barve M, Mennel R, Lenarsky C, Horvath S, Wallraven G, et al. Three-year follow up of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy (Vigil) in metastatic advanced Ewing's sarcoma. Mol Ther. 2016 Aug;24(8):1478–1483. doi:<a href="https://doi.org/10.1038/mt.2016.86." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/mt.2016.86.</a> Epub 2016 Apr 25. PMID: 27109631; PMCID: PMC5023386.
Open DOI Search in Google Scholar Back to article

DOI: https://doi.org/10.2478/fco-2021-0005 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X

Journal RSS Feed

Language: English

Page range: 3 - 27

Submitted on: Jul 13, 2020

Accepted on: Jan 9, 2021

Published on: Feb 1, 2022

Published by: Helenic Society of Medical Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 2 times per year

Keywords:

Related subjects:

Haematology, oncology

© 2022 Jose Duran Moreno, Georgios Papageorgiou, Ioanna Gazouli, Anastasios Kyriazoglou, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 12 (2021): Issue 3 (December 2021)Next article